ETF Holdings Breakdown of CLDX

News associated with CLDX

Tudor Investment Corp ET AL Takes Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Tudor Investment Corp ET AL purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 32,545 shares of the biopharmaceutical company’s stock, valued at approximately $822,000. Other hedge […] - 2025-05-08 08:26:55

Brokerages Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $55.30

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy […] - 2025-05-05 05:35:00

Barclays PLC Increases Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Barclays PLC grew its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 9.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 142,914 shares of the biopharmaceutical company’s stock after buying an additional 12,533 shares during the period. Barclays PLC […] - 2025-04-29 08:19:03

JPMorgan Chase & Co. Acquires 43,470 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

JPMorgan Chase & Co. grew its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 103.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 85,545 shares of the biopharmaceutical company’s stock after buying an additional 43,470 shares during the quarter. JPMorgan […] - 2025-04-24 07:14:49

Renaissance Technologies LLC Makes New $3.45 Million Investment in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Renaissance Technologies LLC bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 136,588 shares of the biopharmaceutical company’s stock, valued at approximately $3,452,000. Renaissance Technologies LLC owned about 0.21% […] - 2025-04-23 07:37:03

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC cut its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 0.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,534,916 shares of the biopharmaceutical company’s stock after selling 5,597 shares during the quarter. Geode Capital […] - 2025-04-16 07:40:52

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation […] - 2025-04-07 06:06:58

American Century Companies Inc. Raises Stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

American Century Companies Inc. raised its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 46.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 608,457 shares of the biopharmaceutical company’s stock after purchasing an additional 193,093 […] - 2025-04-01 08:38:51

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight research firms that are covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-03-13 06:20:51

Celldex Therapeutics (NASDAQ:CLDX) Reaches New 12-Month Low Following Analyst Downgrade

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Get Free Report) shares hit a new 52-week low on Monday after The Goldman Sachs Group lowered their price target on the stock from $42.00 to $36.00. The Goldman Sachs Group currently has a neutral rating on the stock. Celldex Therapeutics traded as low as $19.66 and last traded at […] - 2025-03-05 06:55:05

Celldex Therapeutics (NASDAQ:CLDX) Price Target Lowered to $36.00 at The Goldman Sachs Group

Celldex Therapeutics (NASDAQ:CLDX – Free Report) had its target price cut by The Goldman Sachs Group from $42.00 to $36.00 in a report released on Monday morning,Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” […] - 2025-03-04 08:26:51

CLDX institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-05-08	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	36,966	USD 721,576 3.1%
2025-05-08	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	39,853	USD 777,931 3.1%
2025-05-08	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,006	USD 19,637 3.1%
Total =		77,825	USD 1,519,144

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer